Sarah N Hamilton1, Ryan Carlson, Haroon Hasan, Shahrad R Rassekh, Karen Goddard. 1. *Department of Surgery, Faculty of Medicine, University of British Columbia †Department of Radiation Oncology, British Columbia Cancer Agency-Vancouver Centre ∥Division of Pediatric Hematology/Oncology/BMT, British Columbia Children's Hospital, Vancouver, BC ‡Department of Oncology, Northeast Cancer Centre, Sudbury, ON, Canada §Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
Abstract
OBJECTIVES: The objective of this study was to determine treatment outcomes and long-term complications in pediatric patients with Ewing Sarcoma treated at the British Columbia Cancer Agency (BCCA). METHODS: A retrospective chart review of 101 pediatric patients (<19 y old) with Ewing Sarcoma diagnosed between 1960 and 2005 was performed. The Kaplan-Meier survival analysis and Cox regression multivariate analysis were used to assess prognostic factors for overall survival (OS) and event-free survival (EFS). RESULTS: The median age at diagnosis was 11 years and the median follow-up for nondeceased patients was 13.5 years. The most common primary tumor locations were lower extremity (33%), pelvis (24%), and thorax (18%). Fifty percent of patients received surgery, 79% radiotherapy and 94% chemotherapy. The 5-year OS and EFS for patients with localized disease was 85% and 73% and for metastatic disease was 27% (P<0.0001) and 28% (P<0.0001), respectively. Metastatic disease was an independent predictor of lower OS (hazard ratio [HR], 9.5; 95% confidence interval [CI],4.7-19.4; P<0.0001) and EFS (HR, 4.9; 95% CI, 2.7-8.8; P<0.0001). Extremity tumor location was an independent predictor for improved OS (HR, 0.4; 95% CI, 0.2-0.9; P=0.03). The majority (77%) of long-term survivors (≥5 y) had long-term complications; the most common were musculoskeletal abnormalities (50%) and cardiac toxicity (28%). The actuarial second neoplasm risk was 5% at 10 years. CONCLUSIONS: Ewing sarcoma patients with localized disease had excellent treatment outcomes at the BCCA. However, the majority of patients had chronic complications from treatment. This study validates the need for long-term follow-up of Ewing Sarcoma survivors for management of late effects.
OBJECTIVES: The objective of this study was to determine treatment outcomes and long-term complications in pediatric patients with Ewing Sarcoma treated at the British Columbia Cancer Agency (BCCA). METHODS: A retrospective chart review of 101 pediatric patients (<19 y old) with Ewing Sarcoma diagnosed between 1960 and 2005 was performed. The Kaplan-Meier survival analysis and Cox regression multivariate analysis were used to assess prognostic factors for overall survival (OS) and event-free survival (EFS). RESULTS: The median age at diagnosis was 11 years and the median follow-up for nondeceased patients was 13.5 years. The most common primary tumor locations were lower extremity (33%), pelvis (24%), and thorax (18%). Fifty percent of patients received surgery, 79% radiotherapy and 94% chemotherapy. The 5-year OS and EFS for patients with localized disease was 85% and 73% and for metastatic disease was 27% (P<0.0001) and 28% (P<0.0001), respectively. Metastatic disease was an independent predictor of lower OS (hazard ratio [HR], 9.5; 95% confidence interval [CI],4.7-19.4; P<0.0001) and EFS (HR, 4.9; 95% CI, 2.7-8.8; P<0.0001). Extremity tumor location was an independent predictor for improved OS (HR, 0.4; 95% CI, 0.2-0.9; P=0.03). The majority (77%) of long-term survivors (≥5 y) had long-term complications; the most common were musculoskeletal abnormalities (50%) and cardiac toxicity (28%). The actuarial second neoplasm risk was 5% at 10 years. CONCLUSIONS:Ewing sarcomapatients with localized disease had excellent treatment outcomes at the BCCA. However, the majority of patients had chronic complications from treatment. This study validates the need for long-term follow-up of Ewing Sarcoma survivors for management of late effects.
Authors: Michele Dowless; Caitlin D Lowery; Terry Shackleford; Matthew Renschler; Jennifer Stephens; Robert Flack; Wayne Blosser; Simone Gupta; Julie Stewart; Yue Webster; Jack Dempsey; Alle B VanWye; Philip Ebert; Philip Iversen; Jonathan B Olsen; Xueqian Gong; Sean Buchanan; Peter Houghton; Louis Stancato Journal: Clin Cancer Res Date: 2018-08-21 Impact factor: 12.531
Authors: Maurizio Ghisoli; Minal Barve; Robert Mennel; Carl Lenarsky; Staci Horvath; Gladice Wallraven; Beena O Pappen; Sam Whiting; Donald Rao; Neil Senzer; John Nemunaitis Journal: Mol Ther Date: 2016-04-25 Impact factor: 11.454
Authors: Yu-Chien Kao; Adepitan A Owosho; Yun-Shao Sung; Lei Zhang; Yumi Fujisawa; Jen-Chieh Lee; Leonard Wexler; Pedram Argani; David Swanson; Brendan C Dickson; Christopher D M Fletcher; Cristina R Antonescu Journal: Am J Surg Pathol Date: 2018-05 Impact factor: 6.394
Authors: Choh Yeung; Anna E Gibson; Sameer H Issaq; Nobu Oshima; Joshua T Baumgart; Leah D Edessa; Ganesha Rai; Daniel J Urban; Michelle S Johnson; Gloria A Benavides; Giuseppe L Squadrito; Marielle E Yohe; Haiyan Lei; Sandy Eldridge; John Hamre; Tyrone Dowdy; Victor Ruiz-Rodado; Adrian Lita; Arnulfo Mendoza; Jack F Shern; Mioara Larion; Lee J Helman; Gordon M Stott; Murali C Krishna; Matthew D Hall; Victor Darley-Usmar; Leonard M Neckers; Christine M Heske Journal: Cancer Res Date: 2019-08-20 Impact factor: 12.701
Authors: Christy L Osgood; Nichole Maloney; Christopher G Kidd; Susan Kitchen-Goosen; Laura Segars; Meti Gebregiorgis; Girma M Woldemichael; Min He; Savita Sankar; Stephen L Lessnick; Min Kang; Malcolm Smith; Lisa Turner; Zachary B Madaj; Mary E Winn; Luz-Elena Núñez; Javier González-Sabín; Lee J Helman; Francisco Morís; Patrick J Grohar Journal: Clin Cancer Res Date: 2016-03-15 Impact factor: 12.531
Authors: Jamie C Harris; Jeannine M Coburn; Andre Kajdacsy-Balla; David L Kaplan; Bill Chiu Journal: J Pediatr Surg Date: 2016-09-16 Impact factor: 2.545
Authors: Israel Fernandez-Pineda; M M Hudson; A S Pappo; M W Bishop; J L Klosky; T M Brinkman; D K Srivastava; M D Neel; B N Rao; A M Davidoff; K R Krull; D A Mulrooney; L L Robison; K K Ness Journal: J Cancer Surviv Date: 2016-06-04 Impact factor: 4.442
Authors: Yan Ma; Michael Baltezor; Lian Rajewski; Jennifer Crow; Glenson Samuel; Vincent S Staggs; Katherine M Chastain; Jeffrey A Toretsky; Scott J Weir; Andrew K Godwin Journal: J Mol Med (Berl) Date: 2019-04-25 Impact factor: 5.606